scholarly journals Correction: Interactions of Prototype Foamy Virus Capsids with Host Cell Polo-Like Kinases Are Important for Efficient Viral DNA Integration

2016 ◽  
Vol 12 (10) ◽  
pp. e1005956 ◽  
Author(s):  
Irena Zurnic ◽  
Sylvia Hütter ◽  
Ute Rzeha ◽  
Roger Helbig ◽  
Nicole Stanke ◽  
...  
2016 ◽  
Vol 12 (8) ◽  
pp. e1005860 ◽  
Author(s):  
Irena Zurnic ◽  
Sylvia Hütter ◽  
Ute Rzeha ◽  
Nicole Stanke ◽  
Juliane Reh ◽  
...  

2007 ◽  
Vol 52 (3) ◽  
pp. 901-908 ◽  
Author(s):  
Edward P. Garvey ◽  
Brian A. Johns ◽  
Margaret J. Gartland ◽  
Scott A. Foster ◽  
Wayne H. Miller ◽  
...  

ABSTRACT The naphthyridinone GSK364735 potently inhibited recombinant human immunodeficiency virus type 1 (HIV-1) integrase in a strand transfer assay (mean 50% inhibitory concentration ± standard deviation, 8 ± 2 nM). As expected based on the structure of the drug, it bound competitively with another two-metal binding inhibitor (K d [binding constant], 6 ± 4 nM). In a number of different cellular assays, GSK364735 inhibited HIV replication with potency at nanomolar concentrations (e.g., in peripheral blood mononuclear cells and MT-4 cells, 50% effective concentrations were 1.2 ± 0.4 and 5 ± 1 nM, respectively), with selectivity indexes of antiviral activity versus in-assay cytotoxicity of at least 2,200. When human serum was added, the antiviral potency decreased (e.g., a 35-fold decrease in the presence of 100% human serum was calculated by extrapolation from the results of the MT-4 cell assay). In cellular assays, GSK364735 blocked viral DNA integration, with a concomitant increase in two-long-terminal-repeat circles. As expected, this integrase inhibitor was equally active against wild-type viruses and mutant viruses resistant to approved drugs targeting either reverse transcriptase or protease. In contrast, some but not all viruses resistant to other integrase inhibitors were resistant to GSK364735. When virus was passaged in the presence of the inhibitor, we identified resistance mutations within the integrase active site that were the same as or similar to mutations arising in response to other two-metal binding inhibitors. Finally, either additive or synergistic effects were observed when GSK364735 was tested in combination with approved antiretrovirals (i.e., no antagonistic effects were seen). Thus, based on all the data, GSK364735 exerted potent antiviral activity through the inhibition of viral DNA integration by interacting at the two-metal binding site within the catalytic center of HIV integrase.


Author(s):  
K�roly Szuhai ◽  
Vladimir Bezrookove ◽  
Joop Wiegant ◽  
Johannes Vrolijk ◽  
Roeland W. Dirks ◽  
...  

Virology ◽  
2018 ◽  
Vol 514 ◽  
pp. 50-56 ◽  
Author(s):  
Jinsun Kim ◽  
Ga-Eun Lee ◽  
Martin Lochelt ◽  
Cha-Gyun Shin

2010 ◽  
Vol 84 (10) ◽  
pp. 5250-5259 ◽  
Author(s):  
Jean L. Mbisa ◽  
Wei Bu ◽  
Vinay K. Pathak

ABSTRACT APOBEC3F (A3F) and APBOBEC3G (A3G) both are host restriction factors that can potently inhibit human immunodeficiency virus type 1 (HIV-1) replication. Their antiviral activities are at least partially mediated by cytidine deamination, which causes lethal mutations of the viral genome. We recently showed that A3G blocks viral plus-strand DNA transfer and inhibits provirus establishment in the host genome (J. L. Mbisa, R. Barr, J. A. Thomas, N. Vandegraaff, I. J. Dorweiler, E. S. Svarovskaia, W. L. Brown, L. M. Mansky, R. J. Gorelick, R. S. Harris, A. Engelman, and V. K. Pathak, J. Virol. 81:7099-7110, 2007). Here, we investigated whether A3F similarly interferes with HIV-1 provirus formation. We observed that both A3F and A3G inhibit viral DNA synthesis and integration, but A3F is more potent than A3G in preventing viral DNA integration. We further investigated the mechanisms by which A3F and A3G block viral DNA integration by analyzing their effects on viral cDNA processing using Southern blot analysis. A3G generates a 6-bp extension at the viral U5 end of the 3′ long terminal repeat (3′-LTR), which is a poor substrate for integration; in contrast, A3F inhibits viral DNA integration by reducing the 3′ processing of viral DNA at both the U5 and U3 ends. Furthermore, we demonstrated that a functional C-terminal catalytic domain is more critical for A3G than A3F function in blocking HIV-1 provirus formation. Finally, we showed that A3F has a greater binding affinity for a viral 3′-LTR double-stranded DNA (dsDNA) oligonucleotide template than A3G. Taking these results together, we demonstrated that mechanisms utilized by A3F to prevent HIV-1 viral DNA integration were different from those of A3G, and that their target specificities and/or their affinities for dsDNA may contribute to their distinct mechanisms.


Retrovirology ◽  
2010 ◽  
Vol 7 (1) ◽  
pp. 45 ◽  
Author(s):  
Kristin Stirnnagel ◽  
Daniel Lüftenegger ◽  
Annett Stange ◽  
Anka Swiersy ◽  
Erik Müllers ◽  
...  

2021 ◽  
Author(s):  
Muthukumar Balasubramaniam ◽  
Santosh Thapa ◽  
Benem-Orom Davids ◽  
Alex Bryer ◽  
Chaoyi Xu ◽  
...  

ABSTRACTHIV-1 replication is durably controlled in certain untreated HIV-1-infected individuals expressing particular human leukocyte antigens (HLA). These HLAs tag infected cells for elimination by presenting specific viral epitopes to CD8+ cytotoxic T-lymphocytes (CTL). In individuals expressing HLA-B27, CTLs primarily target the capsid protein (CA)-derived KK10 epitope. Selection of CA mutation R264K helps HIV-1 escape the CTL response but severely diminishes virus infectivity. Here we report that the R264K mutation-associated infectivity defect arises primarily from impaired viral DNA integration. Strikingly, selection of the compensatory CA mutation S173A or depletion of host cyclophilin A largely rescues the R264K-associated integration and infectivity defects. Collectively, our study reveals novel mechanistic insights into the fitness defect incurred by an HIV-1 variant escaping a CA-directed CTL response.


Sign in / Sign up

Export Citation Format

Share Document